Search clinical trials for: famitinib L docetaxel

Total 5043 results

Jiangsu HengRui Medicine Co., Ltd.
Shanghai Pulmonary Hospital, Shanghai, China

Completed

A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Advanced NSCLC

China
Shanghai Chest Hospital

Not yet recruiting

A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. (CAMFA-L)

NSCLC

China
Pfizer

Completed

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

Neoplasms

Poland, United States, Spain
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Single Dose Study To Study The Absorption, Metabolism And Excretion Of Famitinib

Healthy Subjects

China
Jiangsu HengRui Medicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Terminated

A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Gastroenteropancreatic Neuroendocrine Tumor

China
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University

Completed

Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)

Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

China
Arog Pharmaceuticals, Inc.

Withdrawn

A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

Carcinoma, Non-Small-Cell Lung
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer

ER+ / HER2- Advanced Breast Cancer

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Metastatic Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University; Peking University Cancer Hospital & Institute

Completed

A Study of Famitinib in Patients With Advanced Colorectal Cancer

Colorectal Cancer | Colorectal Cancer Metastatic | Colorectal Cancer Recurrent

China
Fudan University
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer

Breast Neoplasms

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT） (FACT)

Colorectal Cancer Metastatic | Colorectal Cancer Recurrent

China
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University; Shanghai Pulmonary Hospital, Shanghai, China

Suspended

A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Renal Cell Carcinoma | Cervical Cancer | Endometrial Cancer | Urothelial Carcinoma | Ovarian Cancer Recurrent

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Bioequivalence Study of Famitinib Malate on Healthy Chinese Volunteers

Healthy Adult Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Chinese...

Completed

A Phase I Study of Famitinib Malate in Patients With Solid Tumor

Advanced Solid Tumor

China
Jiangsu Province Nanjing Brain Hospital

Recruiting

An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC

NSCLC

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-1802 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Boehringer Ingelheim

Completed

BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I

Carcinoma, Non-Small-Cell Lung

Japan
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

Solid Tumor

China
Pfizer

Completed

AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer

Breast Neoplasms

United States, Canada, Czech Republic, Spain, Germany, Italy, India, United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Non-Small-Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma
Fudan University

Recruiting

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) (BCTOP-T-N01)

TNBC - Triple-Negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Enrolling by invitation

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Cervical Cancer

China
Qian Chu
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma (CAPSTONE)

Sarcomatoid Carcinoma of Lung

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

Collecting Duct Carcinoma

China
Quanli Gao

Recruiting

L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

Non-small Cell Lung Cancer

China
Azaya Therapeutics, Inc.

Completed

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Solid Tumor | Non-Small Cell Lung

United States
AstraZeneca
Quintiles, Inc.

Completed

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)

United States
Korean Breast Cancer Study Group

Unknown

A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer (STORM)

Metastatic Breast Cancer | Recurrent Breast Cancer

Korea, Republic of
Second Affiliated Hospital of Xi'an Jiaotong University

Not yet recruiting

Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure

Non Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

EGFR-mutant Non-Small Cell Lung Cancer

China
Fox Chase Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Suspended

A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

Lymphoma | Advanced Solid Tumor

United States
AB Science

Completed

Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation

Mastocytosis
AB Science

Completed

Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis

Multiple Sclerosis
Beijing Konruns Pharmaceutical Co., Ltd.
West China Hospital; Beijing Tongren Hospital; National Cancer Center/Cancer...

Recruiting

A Phase 1 Study of CX1003 (Kanitinib) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
AB Science

Completed

Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

Multiple Myeloma

France
AB Science

Completed

A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University

Completed

Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma (FMTN-I-LNPC)

Locally Advanced Nasopharyngeal Carcinoma

China
AB Science

Completed

Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis

Mastocytosis
Beijing Konruns Pharmaceutical Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Completed

Kanitinib in Treating Patients With Advanced Solid Tumors

Solid Tumors

China
AB Science

Terminated

Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence

Gastro-Intestinal Stromal Tumour
Ruijin Hospital

Not yet recruiting

Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer

Thyroid Cancer

3

Subscribe